Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Claridgeon Dec 12, 2019 11:05am
114 Views
Post# 30447728

RE:RE:Data @6-month ...

RE:RE:Data @6-month ...Vestor111 ... We all know, as it's been documented by TLT in 2014, that PDT/PDC stimulate the immune system and activates the "eat me / don't eat me" signal, which can prevent recurrences.  The first link below from TLT documents that clearly.

But there are other papers that on top of PDC/PDT, only refer to PDT (without PDC).  But it's not clear whether or not at that moment that they use PDT while still meaning PDT/PDC.  There are simply too many excerpts in the following links that we could discuss.

In the meantime, all these links seem to at least support why, in part or all together, we still have p#5 and p#6 cancer after 540+ days.

But if there's no cancer cells left before the 2nd treatment @6-month, that would mean that our TLD-1433 would not be absorbed.  So light activation would not stimulate anything as there would have been not PDC absorbed. 

But would light alone still stimulate immune response?  We'll leave that to science and scientists.  But the recent findings of TLT regarding to the reversal of the Warburg effect (with just light from its CLT technology (therapeutic) could come as additional support to such claim.

Interesting times ahead, no matter what.


 
________________

vestor111 - (12/12/2019 6:02:27 AM)
RE:Data @6-month ...

Catching up on posts.  Ben could you clarify this statement you made?  I had not heard this nor do I understand the underlying mechanism for such a claim.   Any insights would help.

"And PDT alone can stimulate the immune ssytem."

Perhaps in some PDCs that are unstable? 

My understanding, as with most immune responses with PDCs, that immune cells - largely made of of T-Cells, witness the cellular debris from the PDC activation.  This debris has cancer mutation markers that have been cloaked to the immune system and are now exposed.  The markers can include things such as DNA (perhaps even RNA) mutations and/or certain foreign proteins, that the T-Cells now recognize as foreign and pursue. 

One additional point, recall one ot the findings of the recent paper, recently posted from May 2019, on GBM, ALA (a PDC) showed little to no T-Cell activity whereas 1433 showed considerable T-Cell activity related to the GSM tumors.  Granted both were post activation but in either case, ALA appears to have not stimulated a response.

This was a very important finding - aided by photographic evidence. 

Although we may not see eye to eye on a number of things beyond the realm of TLT, I do respect your digging into the research and bringing it to the boards attention and have often noted that. 

Read more at https://stockhouse.com/companies/bullboard/v_tlt?symbol=v.tlt&postid=30444787#2QcWP7pXLXZ1gxQJ.99

Anyone feel free.  I know there is more than one poster here with a med background. 

The essence of the question: How can a PDC stimulate an immune response without activation? 

Bullboard Posts